To: scaram(o)uche who wrote (229 ) 6/5/2002 12:18:07 PM From: russet Read Replies (1) | Respond to MX-1094,...delivery mechanism that gets the standard NSAID past the gastrointestinal track in an inactive form thus reducing ulcers and bleeding, and into blood circulation where it becomes active and can inhibit pain, and thin the blood (Cox1 and Cox2 inhibition) therefore better than Cox2 inhibitors that are being linked to heart attacks, and yet as powerful as normal NSAIDS in pain relief. http://www.medinox.com/company/corporate/corporate.htm Medinox's scientists have discovered proprietary chemical groups that can be attached to known NSAIDs to make them safer. In Medinox's NSAID program, a known NSAID is joined to a proprietary protective group which results in a new chemical entity that is less damaging to the stomach and intestinal lining. In the stomach and the intestine, the protective group remains intact and does not damage the GI system. When it is absorbed into the circulation, the conjugate is cleaved, freeing the NSAID so that it can perform its anti-inflammatory activities (see figure below). In animal studies, Medinox's novel NSAIDs have delivered the equivalent therapeutic benefits as their parent NSAIDs, but produce substantially fewer GI side effects.
